OBJECTIVES: To conduct Cost-Effectiveness Analysis of introducing Semaglutide Oral and Semaglutide injection for the treatment of diabetes type II from the perspective of the Saudi MOH using Bespoke Utility Mapping Method.

METHODS: Our study combines a bespoke methodology with a rigorous cost-effectiveness analysis (CEA) to assess Semaglutide oral and injectable formulations for Type II Diabetes treatment, tailored for the Saudi Ministry of Health (MOH). Integrating machine learning and advanced statistical modeling, we develop a mapping function using clinical, demographic, and HRQoL data from UK and Saudi Arabian populations. Our approach carefully selected and validated features to predict quality of life scores, ensuring accurate comparison. This approach ensures precise estimation of EQ-5D utility scores essential for evaluating Semaglutide's cost-effectiveness in the Saudi healthcare context in comparison with Tirzepatide. Sensitivity analyses validated the reliability of our bespoke method, offering robust insights into health outcomes and economic impacts crucial for MOH decision-making.

RESULTS: CEA findings underscored Semaglutide's favorable cost-effectiveness profile compared to standard treatments, indicating significant gains in quality-adjusted life years (QALYs) and a more favorable cost-effectiveness ratio (ICER). From a societal perspective, Semaglutide demonstrated lower overall costs relative to existing therapies, highlighting potential economic benefits and improved health outcomes for patients with Type II Diabetes.

CONCLUSIONS: In conclusion, Semaglutide presents as a cost-effective treatment option for Type II Diabetes, offering substantial improvements in health outcomes and economic benefits compared to standard therapies. However, its implementation necessitates careful consideration of budgetary implications and strategic resource management from the perspective of the Saudi Ministry of Health context.